×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Leveraging the Capabilities of Artificial Intelligence and Digital Pathology in Precision Medicine
Session Chair(s)
Greg Morehouse, MS
Senior Manager, RA Device, Combination Products
Abbvie, United States
Through this session, we will explore the advantages of incorporating AI and digital pathology for drug and biomarker discovery as part of a long-term companion diagnostic (CDx) partnership. We will also explore potential regulatory challenges in this ever-evolving space.
Learning Objective : Discuss the importance of a complete development lifecycle of drug and companion diagnostic; Describe a complete development lifecycle of a drug and companion diagnostic; Describe potential regulatory challenges facing AI, Digital Pathology, and CDx development.
Speaker(s)
Panel Discussion: Leveraging the Capabilities of Artificial Intelligence and Digital Pathology in Precision Medicine
Elaine Katrivanos
Tempus AI, United States
Senior Director Regulatory Affairs
Panel Discussion: Leveraging the Capabilities of Artificial Intelligence and Digital Pathology in Precision Medicine
Mark Stewart, PhD
Friends of Cancer Research, United States
Vice President, Science Policy
Panel Discussion: Leveraging the Capabilities of Artificial Intelligence and Digital Pathology in Precision Medicine
Andrew Ciupek, PhD
GO2 for Lung Cancer, United States
Associate Director, Clinical Research
Have an account?